Series B

Astanor Ventures is an impact investor that transforms the agrifood system by fostering innovation from "soil and sea to gut." They operate two complementary investment strategies - Astanor Venture for early-stage companies and Astanor Growth for scaling businesses across the entire agrifood value chain. Their mission centers on building a more resilient planet by investing at the intersection of planetary and human health, using food and agricultural systems as primary levers for change. They support ambitious entrepreneurs developing globally scalable solutions capable of driving systemic change, reconnecting planetary and human health through better nutrition and sustainable farming practices. As a global leader in impact investing, Astanor plays a crucial role in financing and scaling systemic disruption needed to reach ambitious targets set by the Paris Agreement and UN SDGs. With offices across Europe and the US, they demonstrate that there is no trade-off between return and impact - the more successful their portfolio businesses become, the greater the positive impact on both people and the planet.

T1D Fund is the world's first scaled venture fund dedicated exclusively to type 1 diabetes, operating as an impact investment fund that supports promising companies through equity investments and expertise. They focus specifically on accelerating treatments, prevention, and cures for the approximately 9 million people living with T1D globally. The fund operates as a powerful platform for collaboration, using catalytic capital and expertise to de-risk investments and create a flywheel effect that attracts other investors to the T1D space. As a wholly owned, not-for-profit independently run subsidiary of Breakthrough T1D, they leverage their intellectual capital and expert network to offer comprehensive support to portfolio companies, steering them through regulatory, clinical, and commercial milestones. With over $200 million in assets under management and 25+ active portfolio companies, T1D Fund creates significant impact in the diabetes ecosystem by reinvesting 100% of returns to propel continuous progress. Their unique position as subject matter experts combined with access to Breakthrough T1D's extensive network of research, clinical, and medical expertise enables them to transform the landscape of T1D investment and accelerate the development of life-changing therapies.